UNICREDIT BANK/CALL/AMGEN/400/0.1/14.01.26 | Market Closed - BOERSE MUENCHEN 20:41:14 31/05/2024 BST | ||
| 1.53 EUR | +4.08% |
|
| 1 month | +86.59% | ||
| 3 months | +91.25% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 31/05/24 | 1.53 | +4.08% |
| 30/05/24 | 1.47 | +8.89% |
| 29/05/24 | 1.35 | -6.25% |
| 28/05/24 | 1.44 | -12.73% |
| 27/05/24 | 1.65 | +3.12% |
Real-time BOERSE MUENCHEN
Last update May 31, 2024 at 08:41 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | 
UniCredit
|
| WKN | HD28ND |
| ISIN | DE000HD28ND2 |
| Date issued | 29/01/2024 |
| Strike | 400 $ |
| Maturity | 14/01/2026 (592 Days) |
| Parity | 10 : 1 |
| Emission price | 1.73 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.28 € |
|---|---|
| Lowest since issue | 0.69 € |
| Spread | 0.02 € |
| Spread % | 1.27% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
305.8
USD
Average target price
316.3
USD
Spread / Average Target
+3.41%
- Stock Market
- Warrants
- Warrant
